Is Mounjaro a GLP-1 drug — and why does the difference matter?

You've seen 'GLP-1' everywhere, then Mounjaro shows up with two letters

It happens a lot. Someone reads about weight-loss injections, spots GLP-1 on every page, then googles Mounjaro and finds the phrase 'GIP and GLP-1 receptor agonist' instead. Confusing, if you're not a pharmacologist.

Here's the practical version. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It tells the brain you're full, slows the stomach, and nudges the pancreas to manage blood sugar. Medicines like semaglutide (Wegovy) mimic this signal artificially. They latch onto the GLP-1 receptor and hold it on.

Tirzepatide, the active ingredient in Mounjaro, does the same thing with GLP-1, and then also activates the GIP receptor. GIP, glucose-dependent insulinotropic polypeptide, is a second gut hormone released after eating fat and carbohydrate. The two receptors seem to work in concert: switching them both on produces a stronger appetite-reducing effect than either alone. That's the hypothesis the clinical trials were built to test, and the results backed it up. If you want to go deeper on tirzepatide's pharmacology, the full tirzepatide overview covers the mechanism in more detail.

What this means for you, practically, is that Mounjaro is not just a stronger version of a GLP-1 drug, it's a different class of drug that happens to include GLP-1 activity as one of its two pathways. If you're curious about whether GLP-1 and Mounjaro are really the same thing, we explore that question in full detail elsewhere on the site.

What the trial data actually showed for a dual-acting medicine

The SURMOUNT-1 trial enrolled 2,539 adults with obesity and no diabetes. After 72 weeks at the highest dose of Mounjaro (15mg) participants lost an average of around 20–21% of their body weight. That figure, published in the New England Journal of Medicine and referenced in NICE's appraisal of tirzepatide, was larger than anything seen in semaglutide trials at comparable doses.

Then came SURMOUNT-5: a direct head-to-head of tirzepatide against semaglutide 2.4mg in 751 adults over 72 weeks. Tirzepatide produced greater average weight reduction. That result is now part of NICE's technology appraisal TA1026, which also notes that indirect comparisons favour tirzepatide. Worth keeping in mind that Wegovy's newer 7.2mg dose has narrowed the gap somewhat, so the landscape keeps moving.

None of this means Mounjaro is the right medicine for every person. The trial participants who did best were those who also made changes to their diet and activity levels alongside the treatment. The medicine supports appetite reduction, the lifestyle work still matters, and a prescriber's job is partly to help you understand that before you start.

Treatment begins at 2.5mg, a dose chosen to let the body adjust rather than to produce immediate results. The prescriber titrates from there, typically in four-week steps. For context on how that process works in practice, the Mounjaro treatment guide walks through each stage.

So what makes Mounjaro different from Wegovy if both hit GLP-1?

Semaglutide (sold as Wegovy for weight management) activates GLP-1 receptors only. Tirzepatide activates GLP-1 and GIP. The extra pathway appears to amplify the appetite-reducing signal in a way that the GLP-1 route alone doesn't fully replicate. Think of it less as 'more powerful' and more as 'two complementary signals instead of one'.

In terms of how they're taken, both are once-weekly subcutaneous injections. Both are prescription-only. Both slow gastric emptying and both carry a GI-heavy side-effect profile: nausea, diarrhoea, constipation and indigestion are the most commonly reported, typically most noticeable in the first few weeks or after a dose increase, and usually settling with time. The NHS medicines page for tirzepatide lists the full side-effect profile in plain language and is worth reading before you start.

People sometimes ask our prescribers about cost at this point. Mounjaro's list price rose significantly in September 2025, so the pricing picture has shifted for anyone comparing quotes from different providers. That's worth factoring in if you're weighing up your options.

One practical difference that catches people out: Mounjaro can reduce the absorption of oral contraceptive pills, particularly in the early weeks of treatment or after each dose increase. Women taking the pill are advised to use an additional non-oral method during those windows. Semaglutide doesn't carry the same guidance. If you're affected by this, it's the kind of thing to raise at your consultation before your first pen arrives.

Does calling it a GLP-1 drug matter when you're deciding whether to try it?

Honestly, the label is less important than the questions underneath it. Is this medicine licensed for weight management in the UK? Yes, for adults with a BMI of 30 or above, or from 27 with at least one weight-related health condition. Is it backed by substantial clinical evidence? Yes, from a programme that involved thousands of participants across the SURMOUNT trials. Is it right for you specifically? That's what a prescriber is there to work out.

The nomenclature (GLP-1 agonist, dual agonist, GIP/GLP-1 receptor agonist) is how scientists and regulators categorise it. For the person standing in front of the fridge wondering what to eat for tea, what matters is whether a medicine is safe, effective, and genuinely supervised by a clinician who has read your notes. Not just a tick-box system. Our page on tirzepatide as a drug, including how it is classified and regulated, goes into this in more detail if you'd like to read further.

If you have more questions about how tirzepatide fits into the wider landscape of weight management options, or you want to understand more before committing, the FAQs on our site cover a lot of the ground people ask about most. And if you're ready to find out whether Mounjaro is clinically suitable for you, a named prescriber at our GPhC-registered pharmacy reads every consultation the same day it's submitted. No bots, no automated gatekeeping.

You can also find more detail about tirzepatide hydrochloride, the specific salt form used in Mounjaro, if you want to understand exactly what you're being prescribed.

Start your free consultation whenever you're ready, whether that's today or after payday, a Monday or a Bank Holiday, the process is the same.